Myasthenia Gravis, Autoimmune, Experimental


Autoimmune Experimental Myasthenia Gravis

Experimental Autoimmune Myasthenia Gravis, Passive Transfer

Experimental Myasthenia

Experimental Myasthenia Gravis

Experimental Myasthenias

Myasthenia Gravis, Autoimmune Experimental

Myasthenia Gravis, Experimental

Myasthenia Gravis, Experimental Autoimmune

Myasthenia, Experimental

Myasthenias, Experimental

Passive Transfer Experimental Autoimmune Myasthenia Gravis

Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3)